


SOFTWARE

# PERSONALIZED PDFS

22.01.2022

Scientific publishers are creating now more and more dynamic PDFs. Why do we know? There is an unexpected loading delay of a [PDF](#) from [Routledge](#) / [Taylor & Francis](#) group that I observed recently. First I thought about some DDos protection, but is indeed a personalized document.



These websites are all being contacted while creating this PDF:

- ▼ □ top
- ▼ ▲ www.tandfonline.com
  - ▶ □ cloud-reader/dist
  - ▼ □ doi/epub/10.1080
    - ▶ 13571516.2021.1976051?needAccess=true
    - ▶ □ na101/home/literatum/publisher/tandf/journals
    - ▶ □ templates/jsp/cloudReader
  - ▶ ▲ GlobalAccess.[name]
  - ▶ ▲ annotations.scitrus.com
- ▶ ▲ certify-js.alexametrics.com
- ▶ ▲ fonts.googleapis.com
- ▶ ▲ snap.lidcdn.com
- ▶ ▲ static.ads-twitter.com
- ▶ ▲ static.cloudflareinsights.com
- ▶ ▲ www.google-analytics.com
- ▶ ▲ www.googleadservices.com
- ▶ ▲ www.googletagmanager.com
- ▶ □ blob:https://www.tandfonline.com/6b47d13d-4
- ▶ □ widget.html
- ▶ ▽ readerServiceWorker.jsp

Scitrus.com seems to be part of a larger reference organizer network and links to science-connect.io. Alexametric.com is the soon to be retired Alexa internet / Amazon service. Snap.lidcdn.com forwards to px.ads.linkedin.com, the business social network. Then we have Twitter ads, Cloudflare security and Google Analytics. All major players now know that my IP is interested in COVID-19 research. Did I ever agree to submit my IP and time stamp when looking up a rather crude scientific paper?

This is exactly what the German [DFG already warned us](#) about last October


For some time now, the major academic publishers have been fundamentally changing their business model with significant implications for research: aggregation and the reuse or resale of user traces have become relevant aspects of their business. Some publishers now explicitly regard themselves as information analysis specialists. Their business model is shifting from content provision to data analytics.

[Another paper](#) describes the situation as “Forced marriages and bastards”...

My question is : Will Francis & Taylor even do more? The [structure of PDFs](#) allows including objects [including Javascript](#). When examining “document.pdf” using [pdf-parser](#) I could

not find any javascript or my current IP in clear text. I cannot exclude however that the chopped up IP is stamped somewhere in the document. So I will have try again at a later time point and redo a bitwise analysis. of the same PDF delivered on another day.

At least the DFG document says that organisations might argue that such software allows for the prosecution of users of shadow libraries. While I have doubts that this is legal, we already see targeted advertisement as I received this [PDF from Wiley](#) that included an Eppendorf ad.



Pyroptosis: A promising therapeutic target for noninfectious diseases

**Cell Proliferation** | WILEY

Received: 17 July 2021 | Revised: 9 September 2021 | Accepted: 20 September 2021

DOI: 10.1111/cpr.13137

**REVIEW**

**Pyroptosis: A promising therapeutic target for noninfectious diseases**

**Tong Li<sup>1,2,3</sup> | Guangjuan Zheng<sup>1,2,4</sup> | Ben Li<sup>3</sup> | Lipeng Tang<sup>1,2</sup>**

<sup>1</sup>State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China

<sup>2</sup>Department of Pharmacology of Traditional Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China

<sup>3</sup>Department of Pharmacy, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China

<sup>4</sup>Department of Pathology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China

Screenshot 20.1.2022

When I downloaded this document a second time using a different IP it was however identical. Blood/Elsevier only let's you even download only after watching a small slideshow...

The screenshot shows the homepage of the journal *blood*. At the top, there is a banner for a clinical trial: "Learn about NCT04444038 A Phase 3 Open-Label, Randomized Study of Pivoxilatinib (LOXO-305) in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)." Below the banner, the journal's navigation menu includes "ISSUES," "FIRST EDITION," "ABSTRACTS," "COLLECTIONS," "AUTHOR CENTER," and "ABOUT." A search bar and a "Cart" icon are also present. The main content area features an article abstract: "Gasdermin D inhibition prevents neutrophil extracellular trap (NET) formation by blocking the inflammasome." The abstract includes the authors' names (Camila Mendes S. Silva, Carlos Wagner S. Wunderley, Renato P. Toma, V. Martins, David F. Cizor, Vanessa F. Borges, Verônica E. Toller, Kawayaco, Sabrina S. Batah, Ana Leticia I. Souza, V. Marco G. Borges, Fausto Almeida, Helder T. Nakaya, Alexandre Ferreira, and C. M. P. da Cunha) and the journal's volume and issue information: "Volume 138, Issue 25 December 23 2021." To the right, there is a sidebar for "Potential Articles of Interest" with a link to "Old drug revisited: dasulimus, NETs, and sepsis" by Mariano Molano et al. in *blood*. The bottom of the page shows a "Connected Content" section and a "Key Points" section with a bullet point: "Inhibition of GSMD with dasulimus abrogates NET formation, reducing multiple organ dysfunction and sepsis lethality." The page footer includes links to "Previous Article" and "Next Article".

Screenshot 20.1.2022

CC-BY-NC Science Surf accessed 02.02.2026

PAGES: 1 2 3 4